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Abstract The AD-4/ACE collaboration studies the biological effects of antiprotons
with respect to a possible use of antiprotons in cancer therapy. In vitro experiments
performed by the collaboration have shown an enhanced biological effectiveness for
antiprotons relative to protons. One concern is the normal tissue dose resulting from
secondary neutrons produced in the annihilation of antiprotons on the nucleons of
the target atoms. Here we present the first organ specific Monte Carlo calculations
of normal tissue equivalent neutron dose in antiproton therapy through the use
of a segmented CT-based human phantom. The MCNPX Monte Carlo code was
employed to quantify the peripheral dose for a cylindrical spread out Bragg peak
representing a treatment volume of 1 cm diameter and 1 cm length in the frontal lobe
of a segmented whole-body phantom of a 38 year old male. The secondary neutron
organ dose was tallied as a function of energy and organ.
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1 Introduction
Today, radiation therapy is one of the prominent treatments of cancer, both curative
as well as palliative. For conventional photon irradiation, the maximum dose that
can be delivered to a tumor is often limited by the tolerance of irradiated adjacent
normal tissues. For many types of tumors, this has led to unacceptably low tumor
control probability (TCP) and to high levels of morbidity. An alternative approach
involves the use of protons and other heavier ions [1–4]. As R. R. Wilson pointed
out in 1946 [5], for these charged particles both the amount and rate of energy
deposition increase dramatically as the particle nears the end of its range. This results
in a large enhancement in absorbed dose at a precise depth in tissue (the Bragg
peak) compared with the dose deposited at the entrance to the body. For treatment
purposes, the position of the Bragg peak needs to be spread out to cover the tumor
volume and the production of such a spread-out Bragg peak (SOBP) results in a build
up of plateau dose and hence a reduction in the ratio of dose in the SOBP relative
to the plateau. However, in contrast to photons, for a given beam direction, the dose
in the SOBP that covers the tumor volume always remains larger than that in the
normal tissue entrance region.
High linear energy transfer (LET) particles such as carbon ions produce a much
higher ionization density in the Bragg peak region than protons and consequently
provide an increase in the relative biological effectiveness (RBE) of the dose
deposited in the tumor [6–8]. This provides a potential further therapeutic advantage,
especially for tumors that have a large hypoxic fraction or for those that are resistant
to conventional radiation [9]. Furthermore, since very little dose is deposited distal to
the Bragg peak, charged particles are ideally suited for treatments of tumors close to
radiosensitive regions. While these favorable physical and biological characteristics
have led to recent developments of proton and heavy ion cancer therapy centers
worldwide, the search for possible enhancements of the therapeutic ratio (the ratio
of effective dose delivered to the target region to the dose delivered to normal
tissue) continues. Antiprotons exhibit similar features as protons while in flight, are
intrinsically stable particles, and deposit about twice the energy of protons at the
end of range due to annihilation at rest. This additional energy is deposited partially
by high LET particles, which increases the biological effective dose even further.
The enhanced biological effectiveness of antiproton annihilation in the vicinity of
the Bragg peak is believed to be beneficial in the context of increasing tumor control
while sparing the surrounding healthy tissue.
The AD-4/ACE collaboration is investigating the potential clinical benefit of
antiprotons using the antiproton beam available at the Antiproton Decelerator
(AD) at CERN. Initial experiments with 46.7 MeV antiprotons found the biological
effective dose ratio (BEDR) between peak and plateau to be 4 times higher for
antiprotons than for protons [10]. Recently, we have successfully performed precise
measurement of the depth dose profile of antiprotons with ionization chambers [11]
and alanine detectors [12], and are therefore now able to extract the relative biologi-
cal effectiveness (RBE) of antiproton beams from cell survival measurements. RBE
values for different cell lines and endpoints can be extracted along the beam path
and can be compared with those found for other particle beam modalities such as
carbon ions and protons. The results of the physical dose and biological effectiveness
measurements are used to benchmark particle transport and radiobiology Monte
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Table 1 Multiplicities for
pions, kaons, and heavy ion
production in antiproton
annihilations in a propane
gas target [15]
Bubble chamber simulations 30 in3 of liquid Propane,
220 MeV antiproton Beam
Multiplicities
Agnew et al. MCNPX
π± 3.38 ± 0.08 3.09 ± 0.09
π0 1.60 ± 0.50 1.83 ± 0.05
κ± 0.08 ± 0.02 0.11 ± 0.01
Heavy ions, 3H, 3He 1.29 ± 0.07 1.34 ± 0.07
Carlo codes. Virtual treatment plans based upon the benchmarked Monte Carlo
codes can then help to identify those tumor incidents where antiproton therapy may
offer a decisive advantage over other modalities [13].
One important issue in the assessment of a new treatment modality is any
background dose deposited outside of the primary target. In antiproton annihilation
this background results from medium and long-range annihilation products, predom-
inantly charged pions, high energy gammas, and neutrons. We have launched a major
effort to address this effect using experiments and Monte Carlo calculations utilizing
a variety of code packages. In this report we concentrate on the example of neutron
equivalent dose to out-of-field organs using MCNPX v26F [14].
2 Calculation of neutron equivalent dose
When an antiproton annihilates after being captured by the nucleus of a target atom,
a number of neutrons, depending on the target nucleus, are emitted. The energy
spectrum of these neutrons spans from thermal energies up to several hundred
MeV, with a mean energy of approximately 50 MeV. The biological efficiency of
these neutrons varies with energy and the International Commission on Radiological
Protection (ICRP) has published weighting factors vs. energy for neutrons in human
tissue. Because of the high biological effectiveness of neutrons and their abundance
in the particle spectrum we decided to study the effect in detail.
2.1 Benchmarking of MCNPX
MCNPX is a Monte Carlo transport package that is widely used in clinical appli-
cations. Nevertheless, when applying it to antiproton therapy the code must be
benchmarked against available experimental data to assure that correct physical
models and transport parameters are utilized and the description of the annihilation
process is complete. We have simulated both the bubble chamber experiments by
Agnew et al. [15] and the neutron multiplicity for annihilation of antiprotons at rest in
the center of slabs of 63Cu reported by Polster et al. [16]. The physical models used in
the simulations consisted of the Bertini model for nucleons and pions, the LAQGSM
model was used for all heavy ions and light ions above 940 MeV/nucleon, and the
ISABEL model was used for the remaining the light ions [15]. Our calculations for
Agnews work agreed well with the experimental results after appropriate changes to
the set cut-off energies were incorporated in the code [Table 1].
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Fig. 1 a, b Sagittal and transverse views of the voxelized phantom’s head and the PTV c Resulting
depth dose profiles (physical dose only) in the beam direction inside the brain for the antiproton and
proton simulations, normalized to the same entrance dose
We also found good agreement between the general shape of the energy spectrum
of neutrons produced in the annihilation of antiprotons at rest in the center of a
63Cu slab obtained by MCNPX and the analytical function given by Polster et al.,
but a slight overshoot in two distinct energy regions resulted in a higher overall
neutron multiplicity than reported by Polster [16]. The overshoot may be related
to the difficulties and unknowns in modeling the Polster experiments; however, the
results were found to be adequate for the purposes of establishing an upper estimate
of the neutron equivalent dose.
2.2 Virtual antiproton irradiation of a voxelized phantom
To model the biological effect of a patient treatment with antiprotons we used a
voxelized phantom of a 38 year old living man (Golem) of approximately the same
dimensions as the ICRP Man [17]. Golem has a weight of 68.9 kg and a height of
176 cm. The voxel size is 34.6 mm3. The planning target volume (PTV) consisted
of a cylinder of 1 cm diameter and 1 cm length situated in the central lobe as
shown in Fig. 1. Comparative simulations were performed for both antiprotons and
protons using active beam modulation. Spread-out Bragg peaks were generated by
modulating the intensities and beam energies between 74 and 86 MeV, resulting in
the profiles shown in Fig. 1c.
The dose deposited by neutrons resulting from the annihilation in the target was
tallied for the individual organs of Golem as a function of neutron energy. The value
for the normal tissue dose received by the brain was obtained by subtracting the
tumor dose estimated using a mesh tally covering the target volume with a 1.5 mm
margin from the total dose. Using the neutron dose as a function of energy obtained
from MCNPX and the neutron radiation weighting factors given as a function of
energy by ICRP, the physical dose in the different organs was then transformed
to equivalent dose by integrating the product of the physical dose and radiation
weighting factors over all energy bins. The resulting organ equivalent doses per
gray of physical dose delivered to the target region for the antiproton and proton
treatments are presented in Table 2 for a number of organs (simulation error implied
by decimal point).
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Table 2 Comparison of neutron equivalent dose for selected organs, normalized to unit physical
dose to the tumor for the given antiproton and proton treatments
Comparison of neutron equivalent dose per Gy in SOBP (Sv/Gy)
Antiprotons (ICRP 92) Protons (ICRP 92)
Brain 8.2 × 10−4 1.2 × 10−5
Thyroid 2.8 × 10−5 3.1 × 10−7
Bone 2.2 × 10−5 3.8 × 10−7
Lung 9.7 × 10−6 8.4 × 10−8
Liver 4.8 × 10−6 3.8 × 10−8
Ceacum, colon, rectum 2.4 × 10−6 1.4 × 10−8
For the purpose of generality, the enhanced SOBP RBE of antiprotons is not incorporated in this
table
3 Conclusions
Using an anthropomorphic phantom, the first Monte Carlo estimates of tissue specific
neutron equivalent dose in antiproton therapy have been produced. For scanning
energy modulation, and a 1 cm cylindrical PTV in the brain, the calculated neutron
equivalent doses for the organs of Golem range from .0001 to .8 mSv per Gy of
SOBP, depending on the proximity to the SOBP. In order to properly compare
these results with that of proton therapy, the enhanced RBE for antiprotons in the
SOBP must be considered in addition to the physical dose normalized comparisons
of Table 2. Using the results from [10] this suggests that the neutron equivalent dose
for antiproton therapy is roughly 60 times higher than what is obtained with protons
for the given treatment plan. Here it should be noted that most proton therapy
centers currently use passive scattering methods for beam delivery which increases
the radiation level to the patient by 1–2 orders of magnitude [18]. Such delivery
techniques are precluded for antiprotons by both the scarcity of these exotic particles
and the high production rate for neutrons and pions by antiprotons interacting with
the material of apertures and compensators. Future work will include a treatment
plan which takes into account the RBE variation along the beam path. This will lower
the actual number of antiprotons needed to deliver the identical biological effective
dose to the tumor as for the proton treatment prescribed and will therefore reduce
the number of neutrons produced.
In addition to the peripheral neutron dose described here there is also a back-
ground of pions and high-energy photons produced in the antiproton annihilation
event. Preliminary calculations show that the physical dose for these components is
similar to the neutron dose, but as these particles have a low linear energy transfer
we expect the equivalent dose to be below the neutron dose. Monte Carlo studies of
these issues are ongoing in parallel to experimental studies of biological effects in the
peripheral region.
Acknowledgements This work has been performed in the context of the AD-4/ACE collaboration1
and the authors are grateful for the many fruitful discussions with other collaboration members. NB
thanks the Danish Cancer Society for supporting this project with a grant.
1http://www.phys.au.dk/∼hk/ad4homepage.html
318 B.P. Fahimian et al.
Open Access This article is distributed under the terms of the Creative Commons Attribution
Noncommercial License which permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
References
1. Levin, W.P., Kooy, H., Loeffler, J.S., DeLaney, T.F.: Proton beam therapy. Br. J. Cancer 93,
849–854 (2005)
2. Suit, H., Goldberg, S., Niemierko, A., Trofimov, A., Adams, J., Paganetti, H., Chen, G.T.,
Bortfeld, T., Rosenthal, S., Loeffler, J., Delaney, T.: Proton beams to replace photon beams in
radical dose treatments. Acta Oncol. 42, 800–808 (2003)
3. Schulz-Ertner, D., Nikoghosyan, A., Thilmann, C., Haberer, T., Jäkel, O., Karger, C., Scholz, M.,
Kraft, G., Wannenmacher, M., Debus, J.: Carbon ion radiotherapy for chordomas and low-grade
chondrosarcomas of the skull base. Results in 67 patients. Strahlenther. Onkol. 179, 598–605
(2003)
4. Mazeron, J.J., Noel, G., Feuvret, L., Calugaru, V., Racadot, S.: Clinical complementarities be-
tween proton and carbon therapies. Radiother. Oncol. 73, S50–S52 (2004)
5. Wilson, R.R.: Radiological use of fast protons. Radiology 47, 487–491 (1946)
6. Blakely, E.A., Tobias, C.A., Yang, T.C., Smith, K.C., Lyman, J.T.: Inactivation of human kidney
cells by high-energy monoenergetic heavy-ion beams. Radiat. Res. 80, 122–160 (1979)
7. Weyrather, W.K., Kraft, G.: RBE of carbon ions: experimental data and the strategy of RBE
calculation for treatment planning. Radiother. Oncol. 73, S161–S169 (2004)
8. Weyrather, W.K., Ritter, S., Scholz, M., Kraft, G.: RBE for carbon track-segment irradiation in
cell lines of differing repair capacity. Int. J. Radiat. Biol. 75, 1357–1364 (1999)
9. Svensson, H., Ringborg, U., Naslund, I., Brahme, A.: Development of light ion therapy at the
Karolinska Hospital and Institute. Radiother. Oncol. 73, S206–S210 (2004)
10. Holzscheiter, M.H., Bassler, N., Agazaryan, N., Beyer, G., Blackmore, E., DeMarco, J.J., Doser,
M., Durand, R.E., Hartley, O., Iwamoto, K.S., Knudsen, H.V., Landua, R., Maggiore, C.J.,
McBride, W.H, Møller, S.P., Petersen, J., Skarsgard, L.D., Smathers, J.B., Solberg, T.D., Ug-
gerhøj, U.I., Vranjes, S., Withers, H.R., Wong, M., Wouters, B.G.: The biological effectiveness
of antiproton irradiation. Radiother. Oncol. 81, 233–242 (2006)
11. Bassler, N., Holzscheiter, M.H., Jäkel, O., Knudsen, H.V., Kovacevic, S., the AD-4/ACE Collab-
oration: The antiproton depthdose curve in water. Phys. Med. Biol. 53, 793–805 (2008)
12. Bassler N., Hansen J.W., Palmans H., Holzscheiter M.H., Kovacevic S., the AD-4/ACE Collabo-
ration: The antiproton depthdose curve measured with alanine detectors. Nucl Instrum Methods
Phys B 266, 929–936 (2008)
13. Bassler, N., Alsner, J., Beyer, G., DeMarco, J.J., Doser, M., Hajdukovic, D., Hartley, O.,
Iwamoto, K.S., Jäkel, O., Knudsen, H.V., Kovacevic, S., Møller, S.P., Overgaard, J., Petersen,
J.B., Solberg, T.D., Sørensen, B.S., Vranjes, S., Wouters, B.G., Holzscheiter, M.H.: Antiproton
radiotherapy. Radiother. Oncol. 86, 1419 (2008)
14. Waters, L.S.: MCNPX Users Manual, Version 2.3.0. Los Alamos Unclassified Research Docu-
ment LA-UR-02-2607 (2002)
15. Agnew, L.E., Elioff Jr., T., Fowler, W.B., Lander, R.L., Powell, W.M., Segré, E., Steiner, H.M.,
White, H.S., Wiegand, C., Ypsilantis, T.: Antiproton interactions in hydrogen and carbon below
200 MeV. Phys. Rev. 118, 1371–1391 (1960)
16. Polster, D., Hilscher, D., Rossner, H., Schmid, W., Baumann, P., Daniel, H., von Egidy, T.,
Hartmann, F.J., Hofmann, P., Kim, Y.S., Lotfranei, M.S.: Spectra and multiplicities of n, p, d,
t, K±, π± from antiproton annihilation in Cu and U. Phys. Lett., B 300, 317–321 (1993)
17. Petoussi-Henss, N., Zankl, M., Fill, U., Regulla, D.: The GSF family of voxel phantoms. Phys.
Med. Biol. 47, 89–106 (2002)
18. Xu, X.G., Bednarz, B., Paganetti, H.: Phys. Med. Biol. 53, R 193–R 241 (2008)
